Phenotype
|
Fish
|
Conditions
|
Figures
|
ventral wall of dorsal aorta runx1 expression decreased amount, abnormal
|
pkd2ouc2015/ouc2015 + MO3-pkd2
|
control
|
Fig. 3
from Liu et al., 2019
|
ventral wall of dorsal aorta runx1 expression decreased distribution, abnormal
|
pkd2ouc2015/ouc2015 + MO3-pkd2
|
control
|
Fig. 3
from Liu et al., 2019
|
hematopoietic progenitor cell differentiation decreased occurrence, abnormal
|
pkd2ouc2015/ouc2015 + MO3-pkd2
|
control
|
Fig. 3
from Liu et al., 2019
|
whole organism chromosome increased amount, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. 8
from Aboualaiwi et al., 2014
|
brain hydrocephalic, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. 4
from Feng et al., 2008
|
whole organism increased curvature, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. 4
from Feng et al., 2008
|
ventral wall of dorsal aorta myb expression decreased distribution, abnormal
|
AB + MO3-pkd2
|
control
|
Fig. 3
from Liu et al., 2019
|
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell decreased amount, abnormal
|
AB + MO3-pkd2
|
control
|
Fig. 5
from Liu et al., 2019
|
post-vent region curved, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. S13
from Pala et al., 2019
Fig. 6
from Zheng et al., 2016
Fig. 8
from Aboualaiwi et al., 2014
|
heart cilium decreased length, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. S14
from Pala et al., 2019
|
ventral wall of dorsal aorta runx1 expression decreased distribution, abnormal
|
AB + MO3-pkd2
|
control
|
Fig. 3 ,
Fig. 5
from Liu et al., 2019
|
pronephric tubule dilated, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. 4
from Zheng et al., 2018
Fig. 7
from Zheng et al., 2016
|
hematopoietic progenitor cell differentiation decreased occurrence, abnormal
|
AB + MO3-pkd2
|
control
|
Fig. 3 ,
Fig. 5
from Liu et al., 2019
|
kidney cystic, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. S13
from Pala et al., 2019
|
artery cilium decreased length, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. S14
from Pala et al., 2019
|
post-vent region curled, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. 4
from Zheng et al., 2018
|
pronephros cystic, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. 4
from Zheng et al., 2018
Fig. 7
from Zheng et al., 2016
Fig. 8
from Aboualaiwi et al., 2014
Fig. 4
from Feng et al., 2008
|
ventral wall of dorsal aorta myb expression decreased amount, abnormal
|
AB + MO3-pkd2
|
control
|
Fig. 3
from Liu et al., 2019
|
heart decreased functionality, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. S13
from Pala et al., 2019
|
ventral wall of dorsal aorta runx1 expression decreased amount, abnormal
|
AB + MO3-pkd2
|
control
|
Fig. 3 ,
Fig. 5
from Liu et al., 2019
|
blood vessel decreased diameter, abnormal
|
AB + MO3-pkd2
|
standard conditions
|
Fig. S13
from Pala et al., 2019
|
whole organism curved dorsal, abnormal
|
AB/TU + MO3-pkd2
|
chemical treatment by environment: valproic acid
|
Fig. 2
from Cao et al., 2009
|
pronephros cystic, abnormal
|
AB/TU + MO3-pkd2
|
chemical treatment by environment: valpromide
|
Fig. 2
from Cao et al., 2009
|
pronephros structure, ameliorated
|
AB/TU + MO3-pkd2
|
chemical treatment by environment: trichostatin A
|
Fig. 1
from Cao et al., 2009
|
pronephros cystic, abnormal
|
AB/TU + MO3-pkd2
|
control
|
Fig. 1
from Cao et al., 2009
|
whole organism curved dorsal, abnormal
|
AB/TU + MO3-pkd2
|
control
|
Fig. 1
from Cao et al., 2009
|
pronephros structure, ameliorated
|
AB/TU + MO3-pkd2
|
chemical treatment by environment: valproic acid
|
Fig. 2
from Cao et al., 2009
|
whole organism curved dorsal, abnormal
|
AB/TU + MO3-pkd2
|
chemical treatment by environment: trichostatin A
|
Fig. 1
from Cao et al., 2009
|
pronephros cystic, ameliorated
|
TL + MO3-pkd2
|
chemical treatment by environment: Brilliant Blue
|
Fig. 7
from Verschuren et al., 2020
|
whole organism decreased life span, abnormal
|
TL + MO3-pkd2
|
standard conditions
|
Fig. 7
from Verschuren et al., 2020
|
pericardium edematous, abnormal
|
TL + MO3-pkd2
|
chemical treatment by environment: Brilliant Blue
|
Fig. 7
from Verschuren et al., 2020
|
post-vent region curvature, ameliorated
|
TL + MO3-pkd2
|
chemical treatment by environment: Brilliant Blue
|
Fig. 7
from Verschuren et al., 2020
|
whole organism life span, ameliorated
|
TL + MO3-pkd2
|
chemical treatment by environment: Brilliant Blue
|
Fig. 7
from Verschuren et al., 2020
|
pronephros cystic, abnormal
|
TL + MO3-pkd2
|
standard conditions
|
Fig. 7
from Verschuren et al., 2020
|
post-vent region curved, abnormal
|
TL + MO3-pkd2
|
standard conditions
|
Fig. 7
from Verschuren et al., 2020
|
pericardium edematous, abnormal
|
TL + MO3-pkd2
|
standard conditions
|
Fig. 7
from Verschuren et al., 2020
|
whole organism Ab3-yap1 labeling decreased amount, abnormal
|
TU + MO3-pkd2
|
standard conditions
|
Fig. 5
from Xu et al., 2018
|
pronephric duct Ab2-scrib labeling decreased amount, abnormal
|
TU + MO3-pkd2
|
standard conditions
|
Fig. 1
from Xu et al., 2018
|
whole organism Ab2-lats1 labeling decreased amount, abnormal
|
TU + MO3-pkd2
|
standard conditions
|
Fig. 5
from Xu et al., 2018
|
whole organism ccn2a expression increased amount, abnormal
|
TU + MO3-pkd2
|
standard conditions
|
Fig. 5
from Xu et al., 2018
|
pronephric duct cystic, abnormal
|
TU + MO3-pkd2
|
standard conditions
|
Fig. 2,
Fig. 5,
Fig. 7
from Xu et al., 2018
|
whole organism Ab2-scrib labeling decreased amount, abnormal
|
TU + MO3-pkd2
|
standard conditions
|
Fig. 1
from Xu et al., 2018
|
whole organism ccn1 expression increased amount, abnormal
|
TU + MO3-pkd2
|
standard conditions
|
Fig. 5
from Xu et al., 2018
|
whole organism Ab3-lats1 labeling decreased amount, abnormal
|
TU + MO3-pkd2
|
standard conditions
|
Fig. 5
from Xu et al., 2018
|
whole organism curved dorsal, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 4
from Sun et al., 2019
|
pronephros morphogenesis decreased process quality, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 3 ,
Fig. 4
from Chang et al., 2017
|
cell proliferation involved in pronephros development increased occurrence, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 4
from Chang et al., 2011
|
post-vent region curved dorsal, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 6
from Arif Pavel et al., 2016
Fig. 9
from Rothschild et al., 2011
Fig. 1
from Yuan et al., 2009
|
pronephric duct anatomical region has extra parts of type leukocyte, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 4
from Chang et al., 2017
|
heart looping disrupted, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 8
from Giamarchi et al., 2010
|
pronephros anterior region truncated, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 9
from Rothschild et al., 2011
|
hypoblast calcium-mediated signaling process quality, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 4
from Yuan et al., 2015
|
brain hydrocephalic, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 6
from Sussman et al., 2014
Fig. 9
from Rothschild et al., 2011
Fig. 8
from Giamarchi et al., 2010
|
post-vent region curved, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 4
from Fogelgren et al., 2011
|
pronephric duct distal region obstructed, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 9
from Rothschild et al., 2011
|
whole organism cAMP-dependent protein kinase activity increased occurrence, abnormal
|
WT + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 5
from Chang et al., 2017
|
pronephros cystic, abnormal
|
WT + MO3-pkd2
|
control
|
FIGURE 4
from Chen et al., 2021
Fig. 4
from Sun et al., 2019
Fig. 6
from Sussman et al., 2014
Fig. 8
from Giamarchi et al., 2010
Fig. 1 ,
Table 2
from Sun et al., 2004
|
pronephric glomerulus increased size, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 8
from Sullivan-Brown et al., 2008
|
pronephric duct epithelial cell proliferation occurrence, ameliorated
|
WT + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 3
from Chang et al., 2017
|
trunk increased curvature, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 6
from Sussman et al., 2014
|
inner ear posterior-most region increased distance pronephric duct anterior-most region, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 9
from Rothschild et al., 2011
|
calcium/calmodulin-dependent protein kinase activity decreased occurrence, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 8
from Rothschild et al., 2011
|
Kupffer's vesicle calcium-mediated signaling process quality, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 2
from Yuan et al., 2015
|
cloacal chamber cilium decreased amount, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 9
from Rothschild et al., 2011
|
post-vent region increased curvature, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 6
from Arif Pavel et al., 2016
Fig. 1 ,
Table 2
from Sun et al., 2004
|
calcium/calmodulin-dependent protein kinase activity decreased rate, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 7
from Francescatto et al., 2010
|
whole organism dcn expression decreased amount, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 6
from Liu et al., 2019
|
gut edematous, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. S1
from Chang et al., 2011
|
protein autophosphorylation decreased occurrence, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 7
from Francescatto et al., 2010
|
cloacal chamber cilium decreased length, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 9
from Rothschild et al., 2011
|
pronephric duct epithelial cell proliferation increased occurrence, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 3
from Chang et al., 2017
|
whole organism Ab1-prkaa labeling increased amount, abnormal
|
WT + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 5
from Chang et al., 2017
|
determination of left/right symmetry process quality, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
text only
from Fogelgren et al., 2011
|
determination of heart left/right asymmetry disrupted, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 8
from Giamarchi et al., 2010
|
pronephros cystic, ameliorated
|
WT + MO3-pkd2
|
chemical treatment by environment: NS-398
|
FIGURE 4
from Chen et al., 2021
|
whole organism increased curvature, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 8
from Giamarchi et al., 2010
|
head hydrocephalic, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 4
from Sun et al., 2019
|
pronephros anterior region structure, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 9
from Rothschild et al., 2011
|
pronephric duct anatomical region has number of leukocyte, ameliorated
|
WT + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 4
from Chang et al., 2017
|
trunk curved dorsal, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 3
from Bouvrette et al., 2010
|
whole organism Ab2-prkaa labeling increased amount, abnormal
|
WT + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 5
from Chang et al., 2017
|
heart mislocalised, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 8
from Giamarchi et al., 2010
|
heart edematous, abnormal
|
WT + MO3-pkd2
|
standard conditions
|
Fig. 8
from Giamarchi et al., 2010
|
determination of heart left/right asymmetry decreased process quality, abnormal
|
WT + MO3-pkd2 + MO9-pkd2
|
standard conditions
|
Fig. 1
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle motile cilium pkd2 expression absent, abnormal
|
WT + MO3-pkd2 + MO9-pkd2
|
standard conditions
|
Fig. 1
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle development process quality, abnormal
|
WT + MO3-pkd2 + MO9-pkd2
|
standard conditions
|
Fig. 4
from Roxo-Rosa et al., 2015
|
post-vent region curved dorsal, abnormal
|
WT + MO3-pkd2 + MO9-pkd2
|
standard conditions
|
Fig. 1
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle cytoplasm pkd2 expression decreased amount, abnormal
|
WT + MO3-pkd2 + MO9-pkd2
|
standard conditions
|
Fig. 1
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle increased area, abnormal
|
WT + MO3-pkd2 + MO9-pkd2
|
standard conditions
|
Fig. 4
from Roxo-Rosa et al., 2015
|
heart mislocalised, abnormal
|
WT + MO3-pkd2 + MO9-pkd2
|
standard conditions
|
Fig. 1
from Roxo-Rosa et al., 2015
|
pronephric duct Ab6-map1lc3b labeling decreased amount, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 7
from Chang et al., 2017
|
vent malformed, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 2
from Chang et al., 2017
|
pronephric duct Ab6-map1lc3b labeling decreased distribution, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 7
from Chang et al., 2017
|
pronephros cystic, ameliorated
|
li1Tg + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 1
from Chang et al., 2017
|
pronephric duct Ab6-map1lc3b labeling amount, ameliorated
|
li1Tg + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 7
from Chang et al., 2017
|
pronephric glomerulus EGFP expression increased distribution, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 6
from Arif Pavel et al., 2016
|
pronephric duct autophagy occurrence, ameliorated
|
li1Tg + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 7
from Chang et al., 2017
|
vent morphology, ameliorated
|
li1Tg + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 2
from Chang et al., 2017
|
post-vent region curved dorsal, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 2
from Chang et al., 2017
|
post-vent region curvature, ameliorated
|
li1Tg + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 2
from Chang et al., 2017
|
pronephric tubule dilated, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 2
from Chang et al., 2011
|
pronephric duct Ab6-map1lc3b labeling spatial pattern, ameliorated
|
li1Tg + MO3-pkd2
|
chemical treatment by environment: metformin
|
Fig. 7
from Chang et al., 2017
|
pronephric duct cystic, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 2
from Chang et al., 2011
|
pronephric glomerulus increased diameter, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 8
from Arhatte et al., 2019
|
pronephric duct autophagy decreased occurrence, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 7
from Chang et al., 2017
|
pronephros cystic, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 1 ,
Fig. 7
from Chang et al., 2017
|
pronephric glomerulus dilated, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 6
from Arif Pavel et al., 2016
Fig. 2
from Chang et al., 2011
|
pronephric glomerulus cystic, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 8
from Arhatte et al., 2019
Fig. 6
from Arif Pavel et al., 2016
|
pronephros morphogenesis decreased process quality, abnormal
|
li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 1 ,
Fig. 7
from Chang et al., 2017
|
heart looping process quality, abnormal
|
twu34Tg + MO3-pkd2
|
standard conditions
|
Fig. 7
from Hurd et al., 2010
|
calcium/calmodulin-dependent protein kinase activity decreased occurrence, abnormal
|
zf34Tg + MO3-pkd2
|
standard conditions
|
Fig. 8
from Rothschild et al., 2011
|
blood vessel cilium decreased length, abnormal
|
hsc5Tg; pku6Tg + MO3-pkd2
|
control
|
Fig. 2
from Liu et al., 2019
|
blood vessel cilium decreased amount, abnormal
|
hsc5Tg; pku6Tg + MO3-pkd2
|
control
|
Fig. 2
from Liu et al., 2019
|
ventral wall of dorsal aorta endothelial cell mCherry expression decreased amount, abnormal
|
jh11Tg; y1Tg + MO3-pkd2
|
control
|
Fig. 6
from Liu et al., 2019
|
pronephric duct cystic, exacerbated
|
lats1zf2211/+ + MO3-pkd2
|
standard conditions
|
Fig. 7
from Xu et al., 2018
|
pronephric duct cystic, exacerbated
|
lats1zf2211/zf2211 + MO3-pkd2
|
standard conditions
|
Fig. 7
from Xu et al., 2018
|
pronephric duct cystic, exacerbated
|
scribzf2209/+ + MO3-pkd2
|
standard conditions
|
Fig. 7
from Xu et al., 2018
|
pronephric duct cystic, exacerbated
|
scribzf2209/zf2209 + MO3-pkd2
|
standard conditions
|
Fig. 7
from Xu et al., 2018
|
post-vent region curvature, ameliorated
|
AB + MO1-fubp1 + MO3-pkd2
|
standard conditions
|
Fig. 6
from Zheng et al., 2016
|
pronephric duct cystic, exacerbated
|
TU + MO2-yap1 + MO3-pkd2
|
standard conditions
|
Fig. 7
from Xu et al., 2018
|
cloacal chamber cilium decreased amount, abnormal
|
WT + MO1-camk2g1 + MO3-pkd2
|
standard conditions
|
Fig. 10
from Rothschild et al., 2011
|
cell migration involved in kidney development disrupted, abnormal
|
WT + MO1-camk2g1 + MO3-pkd2
|
standard conditions
|
Fig. 10
from Rothschild et al., 2011
|
pronephric duct distal region obstructed, abnormal
|
WT + MO1-camk2g1 + MO3-pkd2
|
standard conditions
|
Fig. 10
from Rothschild et al., 2011
|
pronephros anterior region structure, abnormal
|
WT + MO1-camk2g1 + MO3-pkd2
|
standard conditions
|
Fig. 10
from Rothschild et al., 2011
|
inner ear posterior-most region increased distance pronephric duct anterior-most region, abnormal
|
WT + MO1-camk2g1 + MO3-pkd2
|
standard conditions
|
Fig. 10
from Rothschild et al., 2011
|
pronephros anterior region truncated, abnormal
|
WT + MO1-camk2g1 + MO3-pkd2
|
standard conditions
|
Fig. 10
from Rothschild et al., 2011
|
cloacal chamber cilium decreased length, abnormal
|
WT + MO1-camk2g1 + MO3-pkd2
|
standard conditions
|
Fig. 10
from Rothschild et al., 2011
|
post-vent region curved, abnormal
|
WT + MO1-exoc5 + MO3-pkd2
|
standard conditions
|
Fig. 4
from Fogelgren et al., 2011
|
whole organism curved dorsal, exacerbated
|
WT + MO1-hexim1 + MO3-pkd2
|
standard conditions
|
Fig. 4
from Sun et al., 2019
|
whole organism hexim1 expression absent, abnormal
|
WT + MO1-hexim1 + MO3-pkd2
|
standard conditions
|
Fig. 4
from Sun et al., 2019
|
head hydrocephalic, abnormal
|
WT + MO1-hexim1 + MO3-pkd2
|
standard conditions
|
Fig. 4
from Sun et al., 2019
|
pronephros cystic, exacerbated
|
WT + MO1-hexim1 + MO3-pkd2
|
standard conditions
|
Fig. 4
from Sun et al., 2019
|
pronephros morphogenesis decreased process quality, abnormal
|
li1Tg + MO3-pkd2 + MO4-atg5
|
standard conditions
|
Fig. 7
from Chang et al., 2017
|
pronephros cystic, exacerbated
|
li1Tg + MO3-pkd2 + MO4-atg5
|
standard conditions
|
Fig. 7
from Chang et al., 2017
|
heart looping process quality, abnormal
|
twu34Tg + MO2-rp2 + MO3-pkd2
|
standard conditions
|
Fig. 7
from Hurd et al., 2010
|
post-vent region curled, abnormal
|
vu119Tg + MO3-pkd2
|
standard conditions
|
Fig. 3
from Padhy et al., 2022
|
pronephric tubule cystic, abnormal
|
vu119Tg + MO3-pkd2
|
standard conditions
|
Fig. 3
from Padhy et al., 2022
|
trunk curved dorsal, abnormal
|
vu119Tg + MO3-pkd2
|
standard conditions
|
Fig. 3
from Padhy et al., 2022
|
Kupffer's vesicle development process quality, abnormal
|
vu119Tg + MO3-pkd2 + MO9-pkd2
|
control
|
Fig. 2
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle development process quality, abnormal
|
vu119Tg + MO3-pkd2 + MO9-pkd2
|
chemical treatment: CFTRinh-172
|
Fig. 2
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle epithelial cell 3-D shape, abnormal
|
vu119Tg + MO3-pkd2 + MO9-pkd2
|
chemical treatment: forskolin, chemical treatment: 3-isobutyl-1-methyl-7H-xanthine
|
Fig. 3
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle increased volume, abnormal
|
vu119Tg + MO3-pkd2 + MO9-pkd2
|
chemical treatment: forskolin, chemical treatment: 3-isobutyl-1-methyl-7H-xanthine
|
Fig. 2
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle increased volume, abnormal
|
vu119Tg + MO3-pkd2 + MO9-pkd2
|
control
|
Fig. 2
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle volume, ameliorated
|
vu119Tg + MO3-pkd2 + MO9-pkd2
|
chemical treatment: ouabain
|
Fig. S2
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle development process quality, abnormal
|
vu119Tg + MO3-pkd2 + MO9-pkd2
|
chemical treatment: forskolin, chemical treatment: 3-isobutyl-1-methyl-7H-xanthine
|
Fig. 2 ,
Fig. 3
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle decreased volume, abnormal
|
vu119Tg + MO3-pkd2 + MO9-pkd2
|
chemical treatment: CFTRinh-172
|
Fig. 2
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle apical part of cell increased area, abnormal
|
vu119Tg + MO3-pkd2 + MO9-pkd2
|
chemical treatment: forskolin, chemical treatment: 3-isobutyl-1-methyl-7H-xanthine
|
Fig. 3
from Roxo-Rosa et al., 2015
|
pronephric duct cytoplasm EGFP expression decreased amount, abnormal
|
zf2206Tg + MO3-pkd2
|
standard conditions
|
Fig. 5
from Xu et al., 2018
|
pronephric duct nucleus EGFP expression increased amount, abnormal
|
zf2206Tg + MO3-pkd2
|
standard conditions
|
Fig. 5
from Xu et al., 2018
|
Kupffer's vesicle development process quality, abnormal
|
vu119Tg + MO3-pkd2 + MO4-cftr + MO9-pkd2
|
control
|
Fig. 2
from Roxo-Rosa et al., 2015
|
Kupffer's vesicle decreased volume, abnormal
|
vu119Tg + MO3-pkd2 + MO4-cftr + MO9-pkd2
|
control
|
Fig. 2
from Roxo-Rosa et al., 2015
|
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell decreased amount, abnormal
|
pku6Tg; zf169Tg + MO3-pkd2
|
control
|
Fig. 5
from Liu et al., 2019
|
pronephric glomerulus cystic, abnormal
|
tmem33sh443/+; li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 8
from Arhatte et al., 2019
|
pronephric glomerulus increased diameter, abnormal
|
tmem33sh443/+; li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 8
from Arhatte et al., 2019
|
pronephric glomerulus cystic, abnormal
|
tmem33sh443/sh443; li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 8
from Arhatte et al., 2019
|
pronephric glomerulus increased diameter, abnormal
|
tmem33sh443/sh443; li1Tg + MO3-pkd2
|
standard conditions
|
Fig. 8
from Arhatte et al., 2019
|